Optimal management of primary breast cancer

Breast Journal

Volumn 5, Issue 2, 1999, Pages 81-93

  Soran, Atilla ^a   Vogel, Victor G ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b 802 Kaufman Building ^*  (United States)

Author keywords

Breast cancer; Management; Primary; Review

Indexed keywords

GONADORELIN DERIVATIVE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARCINOMA IN SITU; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; SOCIAL ASPECT; TECHNOLOGY;

EID: 0032963081     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1999.00130.x     Document Type: Article

References (115)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancer in 1985. Int J Cancer 1993;54:594-606.
2. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers - 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;54:891-903.
3. Talamonti MS. Management of ductal carcinoma in situ. Semin Surg Oncol 1996;12:300-313.
4. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent on noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastasis, and short-term treatment failures. Cancer 1982;50:1309-14.
5. Fisher ER, Constantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Cancer 1995;75:1310-19.
6. Page DL, Lagios MD. Pathologic analysis of the National Surgical Adjuvant Breast Project (NSBAP) B-17 trial. Unanswered questions remaining unanswered considering current concepts of ductal carcinoma in situ [discussion]. Cancer 1995; 75:1223-27.
7. Chaudhuri B, Crist KA, Mucci S, Malafam M, Chaudhuri PK. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 1993;113:134-37.
8. Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990;66:102-8.
9. Lagios MD, Silverstein MJ. Ductal carcinoma in situ. A shared experience of two single institutional nonrandomized prospective studies. Surg Oncol Clin N Am 1997;6:385-92.
10. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast duct carcinoma in situ. Lancet 1995;345:1154-57.
11. Kinne DW, Petrek JA, Osborne MP, Fracchia AA, De-Palo AA, Rosen PP. Breast carcinoma in situ. Arch Surg 1989; 124:33-36.
12. Warneke J, Grossklaus D, Davis J, et al. Influence of local treatment on the recurrence rate of ductal carcinoma in situ. J Am Coll Surg 1995;180:683-88.
13. Arnesson LG, Smeds S, Fagerberg G, Grontoft O. Follow-up of two treatment modalities for ductal carcinoma in situ of the breast. Br J Surg 1989;76:672-75.
14. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63:618-24.
15. Prince P, Sinnett HD, Gusterson B, Walsh G, A'Hern RP, McKinna JA. Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone. Br J Cancer 1990;61:869-72.
16. Fisher B, Constantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328:1581-86.
17. Huges KS, Lee AK, Rolfs A. Controversies in the treatment of ductal carcinoma in situ. Surg Clin N Am 1996;76:243-65.
18. Zafrani B, Fourquet A, Vilcoq JR, Legal M, Calle R. Conservative management of intraductal breast carcinoma with tumorectomy and radiation therapy. Cancer 1986;57:1299-301.
19. Kuske RR, Bean JM, Garcia DM, et al. Breast conservative therapy for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys 1993;26:391-96.
20. Solin LJ, Recht A, Fourquet A, et al. Ten years result of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer 1991;68:2337-44.
21. Solin LJ, Kurtz J, Fourqet A, et al. Fifteen years results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996;14:754-63.
22. Schwartz GF, Patchefsky AS, Finklestein SD, et al. Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment. Arch Surg 1989;124:29-32.
23. Gump FE, Jicha DL, Ozello L. Ductal carcinoma in situ (DCIS): a revised concept. Surgery 1987;102:790-95.
24. Silverstein MJ, Gierson ED, Colburn WJ, Rosser RJ, Waisman JR, Gamagami P. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 1991; 172:211-14.
25. Morrow M, Schnitt SJ, Harris JR. In situ carcinomas. In: Harris JR, Lippmann ME, Morrow M, Hellman S, eds. Disease of the breast. Philadelphia: Lippincott-Raven, 1996:355-68.
26. Frykberg ER, Ames FC, Bland KI. Current concepts for management of early (in situ and occult invasive) breast carcinoma. In: Bland KI, Copelan EM, eds. The breast. Philadelphia: W.B. Saunders, 1991:733.
27. Haagensen CD. Lobular neoplasia. In: Haagensen CD, ed. Disease of the breast. Philadelphia: W.B. Saunders, 1971: 503-19.
28. Wheeler JE, Enterline HT, Roseman JM, et al. Lobular carcinoma in situ of the breast: long-term follow-up. Cancer 1974;34:554-63.
29. Andersen JA. Lobular carcinoma in situ of the breast: an approach of rational treatment. Cancer 1977;39:2597-602.
30. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232-39.
31. Rosen PP, Kosloff C, Liberman PH, Adair F, Braun DW Jr. Lobular carcinoma of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978;2:225-51.
32. Salvadori B, Bartoli C, Zurrida S, et al. Risk of invasive cancer in women with lobular carcinoma in situ of the breast. Eur J Cancer 1991;27:35-37.
33. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Lobular carcinoma in situ of the female breast: short-term results of prospective nationwide study. Am J Surg Pathol 1993;17:14-21.
34. Fisher ER, Constantino J, Fisher B, et al. Pathologic findings from National Surgical Adjuvant Breast Project (NSAB) protocol B-17. Five years observations concerning lobular carcinoma in situ. Cancer 1996;78:1403-16.
35. Donegan WL, Perez-Mesa CM. Lobular carcinoma: an indication for elective biopsy of the second breast. Ann Surg 1972;176:178-87.
36. Carter D, Smith RL. Carcinoma in situ of the breast. Cancer 1977;40:1189-93.
37. Walt AJ, Simon M, Swanson GM. The continuing dilemma of lobular carcinoma in situ. Arch Surg 1992;127:904-9.
38. Goldschmidt RA, Victor TA. Lobular carcinoma in situ of the breast. Semin Surg Oncol 1996;12:314-20.
39. Carson W, Sanchez-Forgach E, Stomper P, Penetrante R, Tsangaris TN, Edge SB. Lobular carcinoma in situ: observation without surgery as an appropriate therapy. Ann Surg Oncol 1994;1:141-46.
40. Bradley SJ, Weaver DW, Bouwman DL. Alternatives in the surgical management of in situ breast cancer: a metaanalysis of outcome. Am Surg 1990;56:428-32.
41. Smith BL, Bertagnolli M, Klein BB, et al. Evaluation of the contralateral breast. The role of biopsy at the time of the treatment of primary breast cancer. Ann Surg 1992;216:17-21.
42. Frykberg ER, Bland KI. In situ breast carcinoma. Adv Surg 1993;26:29-72.
43. Moore MP, Kinnne DW. Patient selection criteria for conservation surgery versus mastectomy: Memorial Hospital breast service experience. World J Surg 1994;18:58-62.
44. Rosen PP, Grosen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N1M0) breast carcinoma. J Clin Oncol 1989;7:355-66.
45. Halyard MY, Grado GL, Schomberg PJ, Weaver AL, Grant CS, Pisansky TM. Conservative therapy of breast cancer. The Mayo Clinic experience. Am J Clin Oncol 1996;19:445-50.
46. Cheng SH, Chen CM, Jian JJ, et al. Breast conserving surgery and radiotherapy for early breast cancer. J Formos Med Assoc 1996;95:372-77.
47. Neff PT, Bear HD, Pierce CV, et al. Long-term results of breast conservation therapy for breast cancer. Ann Surg 1996;223:709-16.
48. Recht A. Selection of patients with early stage invasive breast cancer for treatment with conservative surgery and radiation therapy. Semin Oncol 1996;23(Suppl 2):19-30.
49. Jacobson JA, Danforth DN, Cowan KH. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332: 907-11.
50. Fowble BL, Orel SG, Jardines L. Conservative surgery and radiation for early -stage breast cancer. Semin Roentgenol 1993;28:279-88.
51. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993;328:1587-91.
52. Gazet JC. Future prospects in limited surgery for early stage cancer. Semin Surg Oncol 1996;12:39-45.
53. Kurtz JM, Amalric R, Brandone H, Ayme Y, Spitalier JM. Local recurrence after breast-preserving surgery and radiotherapy. Helv Chir Acta 1989;55:837.
54. Veronesi U, Salvadori B, Luini A, et al. Conservative treatment of early breast cancer: long-term results of 1232 cases treated with quadranectomy, axillary dissection, and radiotherapy. Ann Surg 1990;211:250-59.
55. Rayter Z, Gazet JC, Ford HT, Easton DF, Coombes RC. Comparison of conservative surgery and radiotherapy with mastectomy in the treatment of early breast cancer. Eur J Surg Oncol 1990;16:486-92.
56. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.
57. Veronesi V, Banfi A, del Vecchio M, et al. Comparison of Halstead mastectomy with quadranectomy axillary dissection and radiotherapy in early breast cancer. Long-term results. Eur J Cancer Clin Oncol 1986;22:1085-89.
58. Carpenter R, Royle GT, Cross M, Hamilton C, Buchanan R, Taylor I. Loco-regional recurrence and survival after wide local excision, radiotherapy and axillary clearance for early breast cancer. J R Soc Med 1992;85:454-56.
59. Staunton MD, Melville DM, Monterrosa A, Thomas JM. A 25-year prospective study of modified radical mastectomy (Patey) in 193 patients. J R Soc Med 1993;86:381-84.
60. Vicini FA, Recht A, Abner A, et al. Recurrence in the breast following conservative surgery and radiation therapy for early-stage breast cancer. J Natl Cancer Inst Monogr 1992;11:33-39.
61. Salvadori B, Biganzoli E, Veronesi P, et al. Conservative surgery for infiltrating lobular breast carcinoma. Br J Surg 1997;84:106-09.
62. Borger J, Kempermann H, Hart A, Peterse H, Van-Dongen J, Bartelink H. Risk factors in breast-conservation therapy. J Clin Oncol 1994;12:653-60.
63. Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25 year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719-25.
64. Sismondi P, Bordon R, Arisio R. Local recurrences after breast conserving surgery and radiotherapy: correlation of histopathological risk factors with age. Breast 1994;3:8-13.
65. Clemente CG, Boracchi P, Anderola S, DelVecchio M, Veronesi P, Rilke FO. Peritumoral lymphatic invasion in patients with node-negative mammary ductal carcinoma. Cancer 1992;69:1396-403.
66. Boyages J, Recht A, Connolly J, et al. Early breast cancer: predictors of breast recurrence for patients treated with limited surgery and radiation therapy. Radiother Oncol 1990; 19:29-41.
67. Ballard-Barbash R, Potosky AL, Harlan LC, Nayfield SG, Kessler LG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 1996;88:716-26.
68. Law TM, Hesketh PJ, Porter KA, Lawn-Tsao L, McAnaw R, Lopez MJ. Breast cancer in elderly women: presentation, survival, and treatment options. Surg Clin N Am 1996; 76:289-308.
69. Solin LJ, Schultz DJ, Fowle BL. Ten-year results of the treatment of early-stage breast carcinoma in elderly women using breast-conserving surgery and definitive breast irradiation. Int J Radiat Oncol Biol Phys 1995;33:45-51.
70. Orel SG, Fowble BL, Solin LJ, Schultz DJ, Conant EF, Troupin RH. Breast cancer recurrence after lumpectomy and radiation for early-stage disease: prognostic significance of detection method. Radiology 1993;188:189-94.
71. Arriagada R, Rutqvist LE, Mattsson A, Kramar A, Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995;13:2869-78.
72. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997;337:949-55.
73. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337:956-62.
74. Marchant DJ. Contemporary management of breast cancer. Obstet Gynecol Clin N Am 1994;21:555-60.
75. Smith RG, Landry JC, Wood WC, et al. Conservative treatment of early-stage breast cancer. The Emory experience. Am J Clin Oncol 1994;17:348-52.
76. Abner AL, Recht A, Eberlein T, et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993;11:44-48.
77. Vicini FA, Horwitz EM, Lacerna MD, et al. The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 1997;39:1069-76.
78. Morrow M, Huffman PC, Weichselbaumb R. Locally advanced breast cancer. In: Harris JR, Hellman S, Henderson IJ, Kinne DW, eds. Breast disease. Philadelphia: JB Lippincott, 1991:767-74.
79. Shen ZZ, Zhang YW, Pan TX, Xia CJ. Multidisciplinary approach to the treatment of unresectable breast cancer. World J Surg 1995;19:843-46.
80. Honkoop AH, Wagstaff J, Pinedo HM. Management of stage III breast cancer. Oncology 1998;55:218-27.
81. Aas T, Geisler S, Paulsen T, et al. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncol 1996;35(Suppl):5-8.
82. Wang HC, Lo SS. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer. Semin Surg Oncol 1996;12:59-66.
83. Bonadonna G, Valagussa P, Zucali R, Salvadori B. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 1995;45:227-43.
84. Singh G, Singh DP, Gupta D, Muralikrishna BV. Neoadjuvant chemotherapy in locally advanced breast cancer. J Surg Oncol 1996;61:38-41.
85. Semiglazov VF, Topuzov EE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994;5:591-95.
86. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M. D. Anderson Cancer Center experience. Surg Oncol Clin N Am 1995;4:715-34.
87. Colozza M, Gori S, Mosconi AM, et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. Am J Clin Oncol 1996;19:10-17.
88. Heys SD, Sarkar TK, Ah-See AK, Eremin JM, Brittenden J, Eremin O. Multimodality treatment in the management of locally advanced breast cancer. J R Coll Surg Edinb 1993;38:9-15.
89. Abdel-wahab M, Wolfson A, Raub W, et al. The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAc, surgery, and radiation, Int J Radiat Oncol Biol Phys 1998;40:875-80.
90. Armstrong DK, Fetting JH, Davidson NE, Gordon GB, Huelskamp AM, Abeloff MD. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat 1993;28:277-84.
91. Gardin G, Rosso R, Campora E, et al. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer 1995;31A:1428-33.
92. Hortobagyi GN, Buzdar AU, Strom EA, Ames FC, Singletary SE. Primary chemotherapy for early and advanced breast cancer. Cancer Lett 1995;90:103-9.
93. Glass JL, Frazee RC. Inflammatory breast cancer. Am Surg 1995;61:121-24.
94. Attia-Sobol J, Ferriere JP, Cure H, et al. Treatment resuits, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer 1993;29A:1081-88.
95. Danforth DN Jr, Lippman ME, McDonald H, et al. Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg 1990;56:6-11.
96. Lopez MJ, Andriole DP, Kraybill WG, Khojasteh A. Multimodal therapy in locally advanced breast carcinoma. Am J Surg 1990;160:669-75.
97. Horobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990;66(Suppl):1378-91.
98. Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys 1989;7:249-55.
99. Brun B, Otmezguine Y, Feuilhade F, et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer 1988; 61:1096-103.
100. Thomas F, Arriagada R, Spielmann M, et al. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer 1995; 76:2286-90.
101. Thomas WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 1989; 17:739-45.
102. Loprinzi CL, Carbone PP, Tormey DC, et al. Aggressive combined modality treatment for advanced local-regional breast cancer. J Clin Oncol 1984;2:157-63.
103. Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach. M. D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 1990;27:94-100.
104. Hortobagyi GN, Singletary SE, McNeese MD. Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippmann ME, Morrow M, Hellman S, eds. Disease of the breast. Philadelphia: Lippincott-Raven, 1996:585-99.
105. Leiagin VP, Sokolova IG, Kondrat'eva AP, Ivanov VM. Combined treatment of primary inoperable breast cancer. Med Radiol 1988;33:41-44.
106. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic and immunotherapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
107. Tabar L, Fagerberg G, Day NE, Duffy SW, Kitchin RM. Breast cancer treatment and natural history: new insights from results of screening. Lancet 1992;339:412-14.
108. Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD. International consensus conference on primary treatment of breast cancer. Recent results. Cancer Res 1996;140:325-35.
109. Robert NJ. Adjuvant therapy in breast cancer. Obstet Gynecol Clin N Am 1994;21:693-707.
110. Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and cases causes of death. J Clin Oncol 1993;11:29-35.
111. Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy in the elderly: competing causes of morbidity. J Clin Oncol 1990;8:519-26.
112. Henderson IC. Adjuvant systemic therapy for early breast cancer. Cancer 1994;74(Suppl):401-9.
113. Misset JL, di Palma M, Delgado M. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubiein, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16 year median follow-up duration. J Clin Oncol 1996;14:1136-45.
114. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer; an overview of the randomized trails. Lancet 1998;351:1451-67.
115. Bezwoda WR, Seymour L, Dansey RD. High dose chemotherapy with hematopoeitic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-89.